Global Multiple Sclerosis Treatment Market – Industry Trends and Forecast to 2030

Global Multiple Sclerosis Treatment, By Type (Clinically isolated syndrome (CIS), Relapse-Remitting MS (RRMS), Primary Progressive MS (PPMS), Secondary Progressive MS (SPMS)), Treatment (Medications, Stem Cell Therapy, Physical Therapy, Plasma Exchange, Others), Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others), Diagnosis (Magnetic Resonance Imaging (MRI), Simple Electrical Stimulation Tests, Lumbar Puncture, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

Multiple Sclerosis Treatment Market Analysis and Size

The multiple sclerosis market is anticipated to grow rapidly during the forecast period. Multiple sclerosis affects about 1 million people in the U.S. and 2.3 million people globally, according to the National Multiple Sclerosis Society. Each year, the number of people diagnosed with multiple sclerosis rises, necessitating the development of new medications that are more effective and have fewer side effects. Governments and non-government organizations in developed and developing countries are increasing their efforts to raise awareness of multiple sclerosis and giving significant funds for drug research and development.                

Data Bridge Market Research analyses that the global multiple sclerosis treatment which was USD 25,123.98 million in 2022, is expected to reach USD 34,723.98 million by 2030, and is expected to undergo a CAGR of 3.3% during the forecast period of 2023 to 2030. “Clinically isolated syndrome (CIS)” dominates the type segment of the global multiple sclerosis treatment due to rising prevalence of multiple sclerosis. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Multiple Sclerosis Treatment Market Scope and Segmentation

Market Definition

Multiple sclerosis (MS) is a chronic inflammatory immune-mediated disease that affects nerve cells in the spinal cord and brain, causing demyelination, axonal transection, and neurodegeneration. Injectable, oral, and infused medications, muscle relaxants, antidepressants, and physical therapy are some of the most widely utilized therapies. Interferon-beta and glatiramer acetate are injectable therapies that are given under the skin or into the muscle; oral medications include teriflunomide, dimethyl fumarate, and cladribine; and intravenous infusion treatments include ocrelizumab, alemtuzumab and natalizumab.

Global Multiple Sclerosis Treatment Dynamics

Drivers

• Increasing Prevalence of Multiple Sclerosis

The primary driver of the global multiple sclerosis treatment market is the rising prevalence of multiple sclerosis worldwide. The disease affects millions of people globally, with varying degrees of severity. As awareness grows and diagnostic techniques improve, more individuals are being diagnosed and seeking treatment. To capitalize on this driver, pharmaceutical companies invest in research and development (R&D) to discover novel treatments and expand their product portfolios.

• Advancements in Treatment Approaches

Ongoing advancements in the treatment of multiple sclerosis have led to the development of disease-modifying therapies (DMTs) that can slow the progression of the disease and manage its symptoms effectively. These innovations have significantly improved the quality of life for MS patients. To harness this driver, manufacturers focus on enhancing the efficacy, safety, and convenience of their treatments.

• Early Diagnosis and Intervention

The emphasis on early diagnosis and intervention in multiple sclerosis has gained momentum. Timely treatment initiation can help manage the disease more effectively and prevent further disability, leading to a growing demand for MS therapies. To address this driver, healthcare systems and providers implement screening and diagnostic programs.

Opportunities

• Emerging Disease-Modifying Therapies

The development of emerging disease-modifying therapies offers potential benefits in terms of enhanced efficacy and safety profiles. These therapies present an opportunity to expand treatment options for MS patients. To harness this opportunity, pharmaceutical companies invest in clinical trials and regulatory approvals.

• Digital Health and Telemedicine

Digital health solutions and telemedicine platforms have become essential tools for managing chronic diseases like multiple sclerosis. Remote monitoring and teleconsultations improve patient access to care and data-driven treatment decisions. To capitalize on this opportunity, manufacturers collaborate with digital health providers and develop companion apps and devices.

Restraints/Challenges

• Adverse Effects and Safety Concerns

Multiple Sclerosis therapies, particularly DMTs, can be associated with adverse effects and safety concerns. Patients may experience side effects that impact their quality of life and treatment adherence. To mitigate this restraint, pharmaceutical companies invest in the development of safer and better-tolerated treatments.

• Complexity of Disease Management

Multiple sclerosis is a complex disease that can manifest differently in each patient. The complexity of disease management can be challenging for healthcare providers and patients alike, leading to treatment delays or suboptimal care. To overcome this restraint, manufacturers invest in educational resources and tools for healthcare providers and patients.

This global multiple sclerosis treatment report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global multiple sclerosis treatment Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In August 2021, Novartis had announced the launch of Kesimpta (ofatumumab) will U.S. Food and Drug Administration (FDA) approval. It is the first and only self-administered, targeted B-cell therapy for the people suffering from relapsing multiple sclerosis. Kesimpta combines potent efficacy with an acceptable safety profile and can be self-administered at home, filling a critical gap in the treatment of replasing forms of multiple sclerosis (RMS)

Global Multiple Sclerosis Treatment Scope

The global multiple sclerosis treatment is segmented on the basis of type, drug class, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Clinically isolated syndrome (CIS)
• Relapse-remitting MS (RRMS)
• Primary progressive MS (PPMS)
• Secondary progressive MS (SPMS)

Treatment

• Medications
• Stem Cell Therapy
• Physical Therapy
• Plasma Exchange
• Others

Drug Class

• Immunomodulators
• Immunosuppressants
• Interferons
• Others

Diagnosis

• Magnetic Resonance Imaging (MRI)
• Simple Electrical Stimulation Tests
• Lumbar Puncture
• Others

Route of Administration

• Oral
• Parenteral
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Multiple Sclerosis Treatment Regional Analysis/Insights

The global multiple sclerosis treatment are analysed and market size insights and trends are provided by type, drug class, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global multiple sclerosis treatment report are U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global multiple sclerosis treatment in terms of market share and market revenue and will continue to flourish its dominance during the forecast period of 2023 to 2030, due of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.

Asia-Pacific on the other hand is projected to exhibit the highest growth rate in the global multiple sclerosis treatment during the forecast period of 2023 to 2030 owing to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global multiple sclerosis treatment also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global multiple sclerosis treatment, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global multiple sclerosis treatment. The data is available for historic period 2015 to 2020.

Competitive Landscape and Global Multiple Sclerosis Treatment Share Analysis

The global multiple sclerosis treatment competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company's focus related to global multiple sclerosis treatment.

Some of the major players operating in the global multiple sclerosis treatment are:

• NIHON KOHDEN CORPORATION (Japan)
• Koninklijke Philips N.V. (Netherlands)
• GENERAL ELECTRIC COMPANY (U.S.)
• Siemens Healthcare Private Limited (Germany)
• Natus Medical Incorporated (U.S.)
• Compumedics Limited (Australia)
• Electrical Geodesics, Inc (U.S.)
• CAS Medical Systems Inc (U.S.)
• Advanced Brain Monitoring (U.S.)
• B. Braun Medical (Germany)
• BD (U.S.)
• DePuySynthes Companies (U.S.)
• Cadwell Industries, Inc. (U.S.)
• Masimo Corporation (U.S.)
• Elekta AB (Sweden)
• Integra LifeSciences Corporation (U.S.)
• Rimed Inc. (Israel)
• Yokogawa Electric Corporation (Japan)
• EMOTIV Inc. (U.S.)